Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERTHENA-Breast02
jRCT2031260321Phase 2Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label trial of patritumab deruxtecan and trastuzumab deruxtecan in breast cancer (4 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Part 1: Number of participants with at least one treatment-emergent adverse event and serious adverse event and Part 2: Objective response per RECIST v1.1 as assessed by the investigator. Started Aug 2026; status: recruiting.
02
Drugs
patritumab deruxtecantrastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031260321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260321.